← Mechanisms of action
Disialoganglioside GD2
SMALL MOLECULEHomo sapiens
Drugs acting on this target (31)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| hu3f4 | Adcc | experimental | mAb | Disialoganglioside GD2 adcc |
| dinutuximab (unituxin) | Binding agent | approved | mAb | Disialoganglioside GD2 binding agent |
| gd2-cart01 | Binding agent | experimental | Cell therapy | Disialoganglioside GD2 binding agent |
| naxitamab (Danyelza) | Binding agent | approved | mAb | Disialoganglioside GD2 binding agent |
| nivatrotamab | Binding agent | experimental | mAb | Disialoganglioside GD2 |
| emd 273063 | Cross-linking agent | experimental | mAb | Disialoganglioside GD2 cross-linking agent |
| morab028 | Cross-linking agent | experimental | mAb | Disialoganglioside GD2 cross-linking agent |
| klh-linked gd2l and gd3l | Immunity, active | experimental | Vaccine | Disialoganglioside GD2 immunity, active |
| 14g2a | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| 177lu-dota-jr11 | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| 4b5 | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| anti-gd2 | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| bi-4scar gd2/cd56 t cells | Immunity, passive | experimental | Cell therapy | Disialoganglioside GD2 immunity, passive |
| bi-4scar gd2/cd70 t cells | Immunity, passive | experimental | Cell therapy | Disialoganglioside GD2 immunity, passive |
| dinutuximab (unituxin) | Immunity, passive | approved | mAb | Disialoganglioside GD2 immunity, passive |
| emd 273063 | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| gd2 car t cells | Immunity, passive | experimental | Cell therapy | Disialoganglioside GD2 immunity, passive |
| gd2, psma and cd276 car-t cells | Immunity, passive | experimental | Cell therapy | Disialoganglioside GD2 immunity, passive |
| gd2bi-aatc | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| ic9-gd2 t cell | Immunity, passive | experimental | Cell therapy | Disialoganglioside GD2 immunity, passive |
| ic9.gd2.car.il-15 t-cells | Immunity, passive | experimental | Cell therapy | Disialoganglioside GD2 immunity, passive |
| monoclonal antibody gd2 anti-idiotype vaccine | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| morab028 | Immunity, passive | experimental | mAb | Disialoganglioside GD2 immunity, passive |
| naxitamab (Danyelza) | Immunity, passive | approved | mAb | Disialoganglioside GD2 immunity, passive |
| 14g2a | Inhibitor | experimental | mAb | Disialoganglioside GD2 inhibitor |
| bcd-245 | Inhibitor | experimental | mAb | Disialoganglioside GD2 inhibitor |
| biw-8962 | Inhibitor | experimental | mAb | Disialoganglioside GD2 inhibitor |
| dinutuximab (unituxin) | Inhibitor | approved | mAb | Disialoganglioside GD2 inhibitor |
| 4b5 | Other | experimental | mAb | Disialoganglioside GD2 other |
| naxitamab (Danyelza) | Other | approved | mAb | Disialoganglioside GD2 other |
| tucotuzumab celmoleukin | Other | experimental | mAb | Disialoganglioside GD2 other |